Stock listing
NASDAQ:ALLO Allogene Therapeutics, Inc. Stock
Home listing (NASDAQ) of Allogene Therapeutics, Inc.
Follow Allogene Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALLO
$0.628 USD -0.068 (-9.8%)
Close on Nov 20, 2026
- Day range
- $0.619 – $0.670 USDNov 20, 2026
- Volume
- 7.58M sharesNov 20, 2026
- Market cap
- $217.5M USDAt the close on Nov 20, 2026 · price × 346.5M shares outstanding
- 52-week range
- $0.619 – $4.460 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.27M USDMedian day 5.99M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALLO · Home | $0.628 USD | -0.068 (-9.8%) | 7,578,372 | $0.642 | $0.670 | $0.619 | $0.696 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALLO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.628 | -0.068 | -9.8% | $0.642 | $0.670 | $0.619 | 7,578,372 | |
| $0.696 | -0.048 | -6.5% | $0.760 | $0.776 | $0.686 | 10,550,720 | |
| $0.744 | -0.063 | -7.8% | $0.800 | $0.815 | $0.740 | 8,487,651 | |
| $0.807 | -0.032 | -3.8% | $0.838 | $0.850 | $0.767 | 8,706,303 | |
| $0.839 | +0.012 | +1.4% | $0.839 | $0.865 | $0.820 | 11,604,145 | |
| $0.827 | -0.073 | -8.1% | $0.890 | $0.897 | $0.822 | 10,627,936 | |
| $0.900 | -0.032 | -3.4% | $0.955 | $0.960 | $0.880 | 15,359,219 | |
| $0.932 | -0.128 | -12.1% | $1.040 | $1.040 | $0.890 | 22,863,434 | |
| $1.060 | +0.020 | +1.9% | $1.100 | $1.100 | $1.000 | 10,731,720 | |
| $1.040 | -0.050 | -4.6% | $1.090 | $1.130 | $0.980 | 12,560,973 | |
| $1.090 | -0.100 | -8.4% | $1.180 | $1.190 | $1.050 | 15,284,769 | |
| $1.190 | +0.070 | +6.2% | $1.160 | $1.200 | $1.120 | 16,527,072 | |
| $1.120 | +0.030 | +2.8% | $1.120 | $1.140 | $1.100 | 17,665,305 | |
| $1.090 | -0.090 | -7.6% | $1.230 | $1.230 | $1.070 | 10,058,285 | |
| $1.180 | -0.070 | -5.6% | $1.240 | $1.258 | $1.160 | 9,758,925 | |
| $1.250 | -0.050 | -3.8% | $1.330 | $1.380 | $1.250 | 7,714,051 | |
| $1.300 | +0.070 | +5.7% | $1.220 | $1.335 | $1.210 | 10,323,337 | |
| $1.230 | +0.020 | +1.7% | $1.210 | $1.260 | $1.170 | 16,102,778 | |
| $1.210 | -0.040 | -3.2% | $1.260 | $1.270 | $1.190 | 10,576,283 | |
| $1.250 | 0.000 | 0.0% | $1.230 | $1.255 | $1.160 | 8,404,820 | |
| $1.250 | -0.080 | -6.0% | $1.320 | $1.330 | $1.220 | 8,296,399 | |
| $1.330 | 0.000 | 0.0% | $1.330 | $1.365 | $1.310 | 4,742,434 | |
| $1.330 | +0.030 | +2.3% | $1.300 | $1.350 | $1.290 | 4,579,577 | |
| $1.300 | -0.010 | -0.8% | $1.300 | $1.330 | $1.260 | 5,906,271 | |
| $1.310 | -0.030 | -2.2% | $1.340 | $1.340 | $1.290 | 4,919,065 | |
| $1.340 | +0.040 | +3.1% | $1.330 | $1.370 | $1.300 | 4,515,192 | |
| $1.300 | +0.010 | +0.8% | $1.280 | $1.308 | $1.220 | 7,736,868 | |
| $1.290 | -0.110 | -7.9% | $1.390 | $1.395 | $1.290 | 6,543,528 | |
| $1.400 | -0.060 | -4.1% | $1.450 | $1.460 | $1.390 | 4,316,472 | |
| $1.460 | +0.060 | +4.3% | $1.390 | $1.480 | $1.370 | 10,605,410 | |
| $1.400 | -0.030 | -2.1% | $1.440 | $1.440 | $1.345 | 7,983,952 | |
| $1.430 | -0.030 | -2.1% | $1.460 | $1.470 | $1.420 | 3,899,722 | |
| $1.460 | -0.040 | -2.7% | $1.500 | $1.500 | $1.430 | 4,659,678 | |
| $1.500 | 0.000 | 0.0% | $1.495 | $1.520 | $1.450 | 4,443,265 | |
| $1.500 | -0.040 | -2.6% | $1.570 | $1.579 | $1.500 | 4,656,621 | |
| $1.540 | -0.060 | -3.8% | $1.600 | $1.610 | $1.530 | 4,606,898 | |
| $1.600 | -0.020 | -1.2% | $1.610 | $1.660 | $1.580 | 8,132,422 | |
| $1.620 | -0.010 | -0.6% | $1.600 | $1.645 | $1.600 | 4,318,917 | |
| $1.630 | -0.020 | -1.2% | $1.650 | $1.665 | $1.600 | 5,026,155 | |
| $1.650 | -0.020 | -1.2% | $1.690 | $1.695 | $1.630 | 3,622,349 | |
| $1.670 | 0.000 | 0.0% | $1.670 | $1.720 | $1.600 | 7,791,092 | |
| $1.670 | -0.040 | -2.3% | $1.730 | $1.740 | $1.650 | 5,965,945 | |
| $1.710 | +0.020 | +1.2% | $1.720 | $1.740 | $1.683 | 5,237,474 | |
| $1.690 | 0.000 | 0.0% | $1.710 | $1.720 | $1.645 | 5,992,401 | |
| $1.690 | -0.040 | -2.3% | $1.730 | $1.740 | $1.670 | 12,716,960 | |
| $1.730 | +0.040 | +2.4% | $1.740 | $1.765 | $1.700 | 3,948,057 | |
| $1.690 | -0.030 | -1.7% | $1.740 | $1.770 | $1.660 | 5,648,084 | |
| $1.720 | -0.060 | -3.4% | $1.800 | $1.800 | $1.710 | 3,138,618 | |
| $1.780 | 0.000 | 0.0% | $1.775 | $1.840 | $1.765 | 7,750,773 | |
| $1.780 | +0.020 | +1.1% | $1.800 | $1.805 | $1.754 | 3,894,350 | |
| $1.760 | +0.030 | +1.7% | $1.730 | $1.780 | $1.695 | 5,401,051 | |
| $1.730 | -0.130 | -7.0% | $1.850 | $1.875 | $1.720 | 7,284,015 | |
| $1.860 | -0.110 | -5.6% | $1.930 | $1.940 | $1.850 | 7,434,268 | |
| $1.970 | -0.010 | -0.5% | $1.970 | $2.010 | $1.950 | 4,428,567 | |
| $1.980 | 0.000 | 0.0% | $2.000 | $2.010 | $1.920 | 4,425,096 | |
| $1.980 | -0.005 | -0.3% | $1.970 | $2.040 | $1.910 | 5,393,709 | |
| $1.985 | -0.015 | -0.7% | $1.960 | $1.999 | $1.930 | 4,037,910 | |
| $2.000 | -0.020 | -1.0% | $2.010 | $2.020 | $1.955 | 4,376,900 | |
| $2.020 | -0.070 | -3.3% | $2.080 | $2.090 | $2.000 | 3,824,689 | |
| $2.090 | +0.050 | +2.5% | $2.040 | $2.140 | $2.000 | 4,982,882 | |
| $2.040 | -0.130 | -6.0% | $2.170 | $2.180 | $2.030 | 5,020,715 | |
| $2.170 | +0.140 | +6.9% | $2.050 | $2.210 | $2.050 | 6,156,769 | |
| $2.030 | -0.060 | -2.9% | $2.110 | $2.110 | $2.000 | 4,755,951 | |
| $2.090 | -0.010 | -0.5% | $2.120 | $2.150 | $2.060 | 4,372,792 | |
| $2.100 | -0.130 | -5.8% | $2.190 | $2.210 | $2.070 | 4,861,236 |
- Ticker
- NASDAQ:ALLO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
Latest earnings call · Nov 5, 2026
Allogene Therapeutics (NASDAQ:ALLO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 12, 2026
Q2 2026 Earnings Presentation
Earnings · 36 slides
Latest news
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
Nov 20, 2026
Closed $0.628 (-9.8%) on Nov 20, 2026
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
Nov 9, 2026
Closed $1.06 (+1.9%) on Nov 9, 2026
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Nov 5, 2026
Closed $1.04 (-4.6%) on Nov 6, 2026
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Nov 3, 2026
Closed $1.12 (+2.8%) on Nov 3, 2026
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Oct 29, 2026
Closed $1.25 (-3.8%) on Oct 29, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Oct 26, 2026
Closed $1.21 (-3.2%) on Oct 26, 2026
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Sep 2, 2026
Closed $1.98 (-0.3%) on Sep 2, 2026
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Aug 12, 2026
Closed $1.98 (-4.3%) on Aug 13, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Aug 4, 2026
Closed $1.90 (+3.3%) on Aug 4, 2026
Allogene Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 186 in all · newest Nov 20, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 5, 2026
- Decks
- 12 decks · latest Aug 12, 2026
Where Allogene Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALLO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALLO | BOATS | United States | USD |
Valuation
EV/sales −1.6× against a median of 99.4×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$7.44M USD
- P/E
- Loss
- EV/sales
- −1.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| Aprilbio Co., Ltd. · KRX:397030 | US$222.4M | US$162.1M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.6M | n/a | 404× | n/a | n/a | n/a | n/a | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Median of the others | US$219.2M | US$160.7M | 99.4× | 1.6× | −130.5% | 0.1× | 1.16 |
Forecasts
8 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.58 · 6 analysts
- Revenue, year to Dec 2026
- 3.78M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Liz Barrett | President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology |
| Zachary Roberts | President and Chief Executive Officer |
| Earl Douglas | General Counsel |
| Leslie Bryant | Executive Director, Corporate Communications |
| Annie Yoshiyama | Senior Vice President, Finance and Corporate Controller, and Principal Accounting Officer |
| Benjamin M. Beneski | Senior Vice President, Chief Technical Officer |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer |
| Geoffrey Parker | Executive Vice President |
| Rocio Manghani | Vice President, Market Access, Evidence & Strategy |
| Allogene Media/Investor Contact:Christine CassianoEVP | Chief Corporate Affairs & Brand Strategy |
| Arie Belldegrun | Executive Chairman and Co-Founder |
| David Chang | Co-Founder |
| Joshua Kazam | Co-Founder and Director |
| Susie Lundeen | Chief People Officer |
Board
| Director | Role |
|---|---|
| Arie Belldegrun | Executive Chairman and Co-Founder |
| David Chang | Co-Founder |
| Franz B. Humer | Lead Independent Director |
| Joshua Kazam | Co-Founder and Director |
| Leslie Bryant | Executive Director, Corporate Communications |
| Liz Barrett | President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology |
| Owen Witte | Professor of Microbiology, Immunology and Molecular Genetics |
| Stephen Mayo | Bren Professor of Biology and Chemistry and Merkin Institute Professor |
| Vicki Sato | Director |
| Zachary Roberts | President and Chief Executive Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Allogene Therapeutics (NASDAQ:ALLO) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q1 2026 Earnings Call | Wed, May 13, 2026 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q4 2025 Earnings Call | Thu, Mar 12, 2026 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q1 2025 Earnings Call | Tue, May 13, 2025 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q4 2024 Earnings Call | Thu, Mar 13, 2025 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 5:00 PM ET | Replay |
| Allogene Therapeutics (NASDAQ:ALLO) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 5:00 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −4.6% |
| Q2 2026 | Aug 12, 2026 · After close | −4.3% |
| Q1 2026 | May 13, 2026 · After close | −8.2% |
| Q4 2025 | Mar 4, 2026 | −8.7% |
| Q3 2025 | Nov 6, 2025 · After close | +12.4% |
| Q2 2025 | Aug 13, 2025 · After close | +2.9% |
| Q1 2025 | May 13, 2025 · After close | −15.7% |
| Q4 2024 | Mar 12, 2025 · Before open | +1.5% |
| Q3 2024 | Nov 7, 2024 · After close | −3.5% |
| Q2 2024 | Aug 7, 2024 · After close | −4.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +2.1% |
| Q4 2023 | Mar 14, 2024 · After close | +3.7% |
| Q3 2023 | Nov 2, 2023 · After close | +17.9% |
| Q2 2023 | Aug 2, 2023 · After close | +9.6% |
| Q1 2023 | May 3, 2023 · After close | +12.8% |
| Q4 2022 | Feb 28, 2023 · After close | −0.2% |
| Q3 2022 | Nov 2, 2022 · After close | −6.4% |
| Q2 2022 | Aug 9, 2022 · After close | +7.8% |
| Q1 2022 | May 4, 2022 · After close | −1.9% |
| Q4 2021 | Feb 23, 2022 · After close | +0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 36 slides | Aug 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Mar 12, 2026 |
| Fact Sheet (September 2025) | Fact sheet | 2 slides | September 2025 |
| ASCO 2025 | Conference | 16 slides | June 2025 |
| Q1 2025 Earnings Presentation | Earnings | 31 slides | May 13, 2025 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 30 slides | 2024 |
| Technical Presentation (June 2023) | Technical | 5 slides | June 2023 |
| ICML 2023 | Conference | 13 slides | June 2023 |
| AACR Annual Meeting 2023 | Conference | 14 slides | April 2023 |
| Technical Presentation (2023) | Technical | 5 slides | 2023 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (December 2022) | Technical | 9 slides | Dec 1, 2022 |
| Technical Presentation (December 2018) | Technical | 15 slides | December 2018 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: US$175M · US$2 a share · Goldman Sachs & Co. LLC +7 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Piper Sandler (co-lead), William Blair (co-lead), TPG Capital BD, LLC, Baird, Canaccord Genuity Use of proceeds: General corporate purposes, which may include clinical trial, R&D, G&A expenses and capital expenditures | Apr 14, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Oct 10, 2018.
- Price
- US$18.00 a share
- Shares offered
- 18,000,000 shares of common stock
- Offering size
- US$324 million
- Underwriters' option
- Up to 2,700,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, J.P. Morgan, Cowen, Jefferies · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 10, 2018 |
| Filed publicly | Sep 14, 2018 |
| Amended 3 times | Newest Oct 5, 2018 |
| Shares registered with an exchange | Oct 5, 2018 |
| Declared effective by the SEC | Oct 10, 2018 |
| Final prospectus, with the price | Oct 11, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 11, 2018 |
| EFFECT · Notice that a registration is effective | Oct 10, 2018 |
| S-1MEF · Registration of more shares for the same offering | Oct 10, 2018 |
| CERT · Exchange's certificate of listing | Oct 10, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2018 |
| S-1/A · Registration statement, amended | Oct 5, 2018 |
| CORRESP · Letter to the SEC | Oct 4, 2018 |
| CORRESP · Letter to the SEC | Oct 4, 2018 |
| CORRESP · Letter to the SEC | Oct 2, 2018 |
| S-1/A · Registration statement, amended | Oct 2, 2018 |
All 17 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 26, 2018 |
| CORRESP · Letter to the SEC | Sep 26, 2018 |
| S-1/A · Registration statement, amended | Sep 17, 2018 |
| CORRESP · Letter to the SEC | Sep 14, 2018 |
| S-1 · Registration statement | Sep 14, 2018 |
| UPLOAD · Letter from the SEC | Sep 11, 2018 |
| DRS · Draft registration statement | Aug 10, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 11, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.0K | 95.0K | 156.0K | 114.1M | 0 | 0 | 0 | 0 |
| Cost of revenue | 12.4M | 13.6M | 14.2M | 16.7M | 13.1M | 11.5M | 5.03M | 1.50M | 0 |
| Gross profit | -12.4M | 22.0K | 95.0K | 243.0K | 38.5M | -11.5M | -5.03M | -1.50M | 0 |
| Research and development | 150.2M | 192.3M | 242.9M | 256.4M | 220.2M | 193.0M | 144.5M | 151.9M | 151.9M |
| Selling, general and administrative | 56.8M | 65.2M | 71.7M | 79.3M | 74.1M | 65.3M | 57.5M | 41.0M | 24.0K |
| Operating income | -209.3M | -273.2M | -327.7M | -335.5M | -180.2M | -258.2M | -202.0M | -192.8M | -2.00K |
| Depreciation and amortization | 12.4M | 13.6M | 14.2M | 14.3M | 10.5M | 7.40M | 4.60M | 1.00M | 24.0K |
| EBITDA | -197.0M | -259.6M | -313.5M | -321.2M | -169.7M | -250.8M | -197.4M | -191.8M | 22.0K |
| Interest expense | 1.07M | 181.0K | 0 | 17.1M | 10.5M | 0 | 0 | 3.36M | 0 |
| Income before tax | -190.9M | -257.1M | -327.3M | -332.6M | -257.0M | -250.2M | -184.9M | -211.6M | -24.0K |
| Income tax | 0 | 443.0K | 0 | 0 | 0 | 0 | -331.0K | -117.0K | -24.0K |
| Net income | -190.9M | -257.6M | -327.3M | -340.4M | -182.1M | -316.4M | -184.6M | -211.5M | -2.00K |
| Earnings per share, basic | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | -7.31 | -0.00 |
| Earnings per share, diluted | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | -7.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 51.7M | 75.2M | 83.2M | 61.9M | 173.3M | 183.4M | 175.1M | 92.4M | 0 |
| Short-term investments | 198.5M | 217.3M | 365.5M | 455.4M | 284.0M | 644.6M | 355.4M | 367.0M | 0 |
| Receivables | 1.50M | 1.90M | 1.70M | 3.30M | 6.00M | 2.80M | 2.40M | 3.11M | |
| Inventory | -62.5M | -62.5M | -20.0M | -207.0M | -60.7M | -262.0M | |||
| Current assets | 257.7M | 303.4M | 459.1M | 528.8M | 471.3M | 845.1M | 544.6M | 468.0M | 0 |
| Property, plant and equipment | 72.8M | 86.1M | 99.5M | 112.8M | 123.0M | 118.8M | 56.4M | 8.60M | |
| Total assets | 415.9M | 548.7M | 642.8M | 821.6M | 1.05B | 1.23B | 717.8M | 773.9M | 0 |
| Accounts payable | 4.27M | 5.39M | 5.90M | 13.9M | 10.3M | 10.4M | 9.25M | 12.3M | 0 |
| Current liabilities | 32.5M | 35.5M | 37.1M | 53.7M | 47.9M | 94.3M | 33.1M | 29.5M | 2.00K |
| Long-term debt | 34.5M | ||||||||
| Total debt | 83.3M | 90.8M | 95.1M | 101.1M | 73.1M | 53.8M | 53.0M | 34.5M | |
| Total liabilities | 123.4M | 126.5M | 130.6M | 154.7M | 125.6M | 148.2M | 88.8M | 70.7M | 2.00K |
| Shareholders' equity | 292.5M | 422.2M | 512.2M | 666.9M | 925.2M | 1.01B | 629.0M | 703.2M | -2.00K |
| Shares outstanding | 229.4M | 212.2M | 168.6M | 144.4M | 142.6M | 140.5M | 124.3M | 121.5M | 44.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -149.2M | -200.3M | -237.7M | -220.5M | -184.8M | -115.1M | -137.3M | -44.7M | -44.7M |
| Capital spending | -386.0K | -694.0K | -1.52M | -5.19M | -21.4M | -66.0M | -50.8M | -3.23M | -5.33M |
| Free cash flow | -149.6M | -201.0M | -239.2M | -225.7M | -206.3M | -181.1M | -188.1M | -47.9M | -50.0M |
| Cash from investing | 95.6M | 75.7M | 163.3M | 106.2M | 163.7M | -505.1M | 164.1M | -632.8M | -632.8M |
| Cash from financing | 30.2M | 116.7M | 95.7M | 2.95M | 12.0M | 633.6M | 59.0M | 771.2M | 771.2M |
| Share buybacks | 895.0K | 1.53M | 2.46M | 2.46M | 3.62M | 2.84M | 1.78M | 654.3M | |
| Change in cash | -23.5M | -7.94M | 21.3M | -111.4M | -9.19M | 13.4M | 85.7M | 93.7M | 93.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 424B5 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | May 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 28, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 20, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2026 | Current report | SEC |
| 424B5 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 10, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 21, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 14, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 3, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Dec 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 13, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | May 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 424B5 · Prospectus | May 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 24, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 22, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 19, 2024 | Other filings | SEC |
This page holds 200 of 588 filings. Open Filings
Cap table
Built by 6ix from Allogene Therapeutics, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 346,467,307
- Fully diluted
- 346,467,307
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 346,467,307 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 346,467,307 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Vicki Sato Other companies: Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jan 2, 2025 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 11, 2019 · Past); BorgWarner Inc. (Director · Feb 12, 2014 – Apr 29, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2007 – Jun 2, 2010 · Past); Bristol-Myers Squibb Company (Director · Jul 11, 2006 – Feb 1, 2021 · Past); Revvity, Inc. (Director · May 2, 2006 – Feb 9, 2017 · Past) | Director · Since at least Jul 30, 2021 |
| Timothy L Moore Other companies: BioLife Solutions, Inc. (Director · Since at least Sep 1, 2022); Cerus Corporation (Director · Since at least Sep 5, 2018); Instil Bio, Inc. (Chief Operating Officer · Sep 6, 2022 – Sep 6, 2022 · Past); Kite Pharma Inc (EVP, Technical Operations · Mar 15, 2016 – Oct 3, 2017 · Past) | Chief Technical Officer · Apr 24, 2023 – Feb 3, 2025 · Past |
| Arie Belldegrun Other companies: UroGen Pharma Ltd. (Director · Since at least Mar 24, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past) | Director · Since at least Mar 26, 2021 |
| Elizabeth A Barrett Other companies: Sage Therapeutics Inc (Director · Since at least Jun 11, 2025); UroGen Pharma Ltd. (Chief Executive Officer · Since at least Jan 3, 2019); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past) | Director · Since at least Jul 30, 2021 |
| Rafael G. Amado Other companies: Zai Lab Ltd. (President, Head of Global Research and Development · Since at least Dec 30, 2022); Poseida Therapeutics Inc (Director · Apr 13, 2023 – Jan 8, 2025 · Past); Adaptimmune Therapeutics PLC (President, R&D · Jan 1, 2016 – Aug 6, 2019 · Past) | EVP of R&D · Sep 3, 2019 – Oct 7, 2022 · Past |
| Deborah M Messemer Other companies: TPG Inc. (Director · Since at least Jan 13, 2022); PayPal Holdings, Inc. (Director · Since at least May 26, 2021) | Director · Since at least Jun 10, 2021 |
| Eric Thomas Schmidt Other companies: Revolution Medicines, Inc. (Director · Jun 17, 2020 – Jun 8, 2023 · Past); Relmada Therapeutics, Inc. (Director · Dec 19, 2019 – May 25, 2023 · Past) | Chief Financial Officer · Oct 10, 2018 – Mar 22, 2023 · Past |
| Geoffrey Parker Other companies: Perrigo Company plc (Director · Since at least May 14, 2024); Better Therapeutics, Inc. (Director · Dec 18, 2023 – Dec 18, 2023 · Past) | CHIEF FINANCIAL OFFICER · Since at least Oct 16, 2023 |
| Stephen L. Mayo Other companies: Sarepta Therapeutics, Inc. (Director · Since at least Nov 16, 2021); Merck & Company, Inc. (Board Member · Since at least Mar 15, 2021) | Bren Professor of Biology and Chemistry and Merkin Institute Professor · Since at least Jul 8, 2022 |
| David Chang Other companies: Kite Pharma Inc (EVP, R&D, Chief Medical Off. · Jun 19, 2014 – Oct 3, 2017 · Past) | Co-Founder · Since at least Oct 10, 2018 |
All 26 people
| Person | Seat |
|---|---|
| Earl Douglas Other companies: Biomimetic Therapeutics Inc (General Counsel · May 10, 2006 – Mar 26, 2012 · Past) | General Counsel · Since at least Aug 14, 2023 |
| Liz Barrett Other companies: UroGen Pharma Ltd. (President and Chief Executive Officer · Since at least Nov 4, 2026) | President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology · Since at least Nov 6, 2026 |
| Allogene Media/Investor Contact:Christine CassianoEVP | Chief Corporate Affairs & Brand Strategy · Since at least Apr 16, 2026 |
| Annie Yoshiyama | Senior Vice President, Finance and Corporate Controller, and Principal Accounting Officer · Since at least Apr 23, 2026 |
| Benjamin M. Beneski | Senior Vice President, Chief Technical Officer · Since at least Jan 29, 2025 |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer · Since at least Nov 3, 2026 |
| Franz B. Humer | Director · Since at least Jun 18, 2025 |
| Joshua Kazam | Co-Founder and Director · Since at least Jun 23, 2026 |
| Leslie Bryant | Executive Director, Corporate Communications · Since at least Nov 3, 2026 |
| Lillian Smith | VP, Corporate Counsel · Apr 1, 2023 – Apr 1, 2023 · Past |
| Owen Witte | Professor of Microbiology, Immunology and Molecular Genetics · Since at least Nov 6, 2026 |
| Rocio Manghani | Vice President, Market Access, Evidence & Strategy · Since at least Nov 5, 2026 |
| Susie Lundeen | Chief People Officer · Since at least Nov 6, 2026 |
| Veer Bhavnagri | General Counsel · Apr 16, 2020 – Mar 14, 2023 · Past |
| Yinlin Jack Chen | SVP, Finance · Aug 10, 2023 – Aug 10, 2023 · Past |
| Zachary Roberts | President and Chief Executive Officer · Since at least Nov 3, 2026 |
Log in to ask 6ix AI your own questions about Allogene Therapeutics, Inc.